OTCMKTS: DNPUF

Japan-based Sumitomo Pharma Co., Ltd (OTCMKTS: DNPUF) has secured market approval in China for Xenleta (lefamulin acetate), a drug indicated for the treatment of community-acquired pneumonia in adults. The approval was obtained through Sumitomo’s Suzhou-based subsidiary, which already has Mepem (meropenem), a carbapenem antibiotic, in its Chinese market portfolio, and…